Pharmaceutical firm Wockhardt Ltd on Tuesday said it has initiated a global Phase III clinical study of its new antibiotic candidate WCK 5222. The company has completed the first
Share this article
If you liked this article share it with your friends.they will thank you later
/newsdrum-in/media/post_banners/HCwRvK2Ll1hyREefV1tS.jpg)
1 Min read
/newsdrum-in/media/agency_attachments/2025/01/29/2025-01-29t072616888z-nd_logo_white-200-niraj-sharma.jpg){kind=logo}
